Cadila Healthcare has received a warning letter from the U.S. Food and Drug Administration for two facilities in Gujarat, India, according to an article in The Telegraph.
The company said it had received an FDA warning letter targeting its formulation facility at Moraiya and an active pharmaceutical ingredient unit (Zyfine) in Ahmedabad. Cadila said there were no products in the United States that used API from the Zyfine facility.
Read the full story
View the most popular news stories in 2015 from Pharmaceutical Manufacturing.
